Monday, August 14, 2006
Drug Wars Update 3
This afternoon, Bristol-Myers Squibb and Sanofi-Aventis, the co-marketers of the blockbuster anti-coagulant Plavix filed a motion for an order (preliminary injunction) barring Apotex from marketing a generic version of the drug. The motion was filed in the federal district court in Manhattan, the court where the Plavix patent litigation is pending. The court has scheduled a hearing for Friday August 18. Bristol Myers CEO Peter Dolan posted a public message about this action.